Relay Therapeutics RLAY Stock
Relay Therapeutics Price Chart
Relay Therapeutics RLAY Financial and Trading Overview
| Relay Therapeutics stock price | 18.73 USD |
| Previous Close | 20.75 USD |
| Open | 19.7 USD |
| Bid | 14.81 USD x 200 |
| Ask | 25.01 USD x 200 |
| Day's Range | 19.31 - 20.75 USD |
| 52 Week Range | 3.03 - 20.79 USD |
| Volume | 3.15M USD |
| Avg. Volume | 4.25M USD |
| Market Cap | 4.36B USD |
| Beta (5Y Monthly) | 1.682 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.56 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.08 USD |
RLAY Valuation Measures
| Enterprise Value | 3.22B USD |
| Trailing P/E | N/A |
| Forward P/E | -12.097993 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 408.38293 |
| Price/Book (mrq) | 5.8942246 |
| Enterprise Value/Revenue | 301.816 |
| Enterprise Value/EBITDA | -10.975 |
Trading Information
Relay Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.682 |
| 52-Week Change | 476.38% |
| S&P500 52-Week Change | 20.51% |
| 52 Week High | 20.79 USD |
| 52 Week Low | 3.03 USD |
| 50-Day Moving Average | 14.97 USD |
| 200-Day Moving Average | 10.26 USD |
RLAY Share Statistics
| Avg. Volume (3 month) | 4.25M USD |
| Avg. Daily Volume (10-Days) | 5.34M USD |
| Shares Outstanding | 217.94M |
| Float | 136.08M |
| Short Ratio | 8.72 |
| % Held by Insiders | 1.37% |
| % Held by Institutions | 87.08% |
| Shares Short | 43.04M |
| Short % of Float | 23.02% |
| Short % of Shares Outstanding | 19.75% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2619.66% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -24.72% |
| Return on Equity (ttm) | -40.0079% |
Income Statement
| Revenue (ttm) | 10.68M USD |
| Revenue Per Share (ttm) | 0.06 USD |
| Quarterly Revenue Growth (yoy) | -60.89% |
| Gross Profit (ttm) | -245584000 USD |
| EBITDA | -293606016 USD |
| Net Income Avi to Common (ttm) | -272704992 USD |
| Diluted EPS (ttm) | -1.5 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 642.07M USD |
| Total Cash Per Share (mrq) | 3.35 USD |
| Total Debt (mrq) | 31.57M USD |
| Total Debt/Equity (mrq) | 4.92 USD |
| Current Ratio (mrq) | 22.132 |
| Book Value Per Share (mrq) | 3.394 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -213356992 USD |
| Levered Free Cash Flow (ttm) | -121180872 USD |
Profile of Relay Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 60 Hampshire Street |
| ZIP | 02139 |
| Phone | 617 370 8837 |
| Website | https://www.relaytx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 193 |
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Q&A For Relay Therapeutics Stock
What is a current RLAY stock price?
Relay Therapeutics RLAY stock price today per share is 18.73 USD.
How to purchase Relay Therapeutics stock?
You can buy RLAY shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Relay Therapeutics?
The stock symbol or ticker of Relay Therapeutics is RLAY.
Which industry does the Relay Therapeutics company belong to?
The Relay Therapeutics industry is Biotechnology.
How many shares does Relay Therapeutics have in circulation?
The max supply of Relay Therapeutics shares is 217.94M.
What is Relay Therapeutics Price to Earnings Ratio (PE Ratio)?
Relay Therapeutics PE Ratio is now.
What was Relay Therapeutics earnings per share over the trailing 12 months (TTM)?
Relay Therapeutics EPS is -1.56 USD over the trailing 12 months.
Which sector does the Relay Therapeutics company belong to?
The Relay Therapeutics sector is Healthcare.
Relay Therapeutics RLAY included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25873.18 USD — |
-1.55
|
6.31B USD — | 25822.1 USD — | 26139.37 USD — | — - | 6.31B USD — |
|
US Tech Health Care
IXHC
US
|
1254.95 USD — |
-1.05
|
— — | 1250.11 USD — | 1262.34 USD — | — - | — — |
|
US Tech Global Market Composite
NQGM
US
|
2276 USD — |
-2.23
|
— — | 2272.18 USD — | 2307.6 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3154.19 USD — |
-0.65
|
— — | 3147.71 USD — | 3174.71 USD — | — - | — — |
|
US Tech AlphaDEX Multi Cap Growt
NQDXUSMLTCG
US
|
4006.39 USD — |
-1.69
|
— — | 3993.97 USD — | 4049.67 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6546.6 USD — |
-1.47
|
— — | 6508.46 USD — | 6585.47 USD — | — - | — — |
- {{ link.label }} {{link}}